TNF and COVID-19: While there may be a subset of patients who may potentially benefit from the use of tocilizumab, current evidence does not support the routine use of tocilizumab or other drugs that regulate host immune response (i.e., anti-IL1, anti-TNFα) in COVID-19 or non-COVID-19 sepsis.